EMA Recommends Extension of Indications for Serplulimab By Ogkologos - April 22, 2026 3 0 Facebook Twitter Google+ Pinterest WhatsApp New indications concern the treatment of patients with oesophageal squamous cell carcinoma and non-small cell lung cancer Source RELATED ARTICLESMORE FROM AUTHOR Adding Relacorilant to Nab-paclitaxel Prolongs OS in Patients with Platinum-Resistant Ovarian Cancer Quadruplet Isa-KRd Regimen Improves NGS-MRD Negativity in Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma EMA Recommends Granting a Marketing Authorisation for Tarlatamab MOST POPULAR Regular Exercise May Boost Immune Response and Improve Immunotherapy in Breast... April 13, 2021 Adjuvant Everolimus Does Not Improve Recurrence-Free Survival Among Patients with Renal... August 9, 2023 EMA Recommends Extension of Indications for Selumetinib October 9, 2025 From Awareness to Action: Putting Cancer Disparities in the Rearview Mirror March 21, 2024 Load more HOT NEWS Army Veteran Gets Life-Saving Heart Transplant: ‘It’s A True Miracle’ Wawa Employee Saves Life Of Customer Who Stopped Breathing After A... Study Provides Closer Look at Postmenopausal Bleeding and Endometrial Cancer ΚΑΡΚΙΝΟΣ ΠΑΓΚΡΕΑΤΟΣ